Evidence map›Paper›PMID 38659573›Full record

ReviewFrontiers in pharmacology2024

The potential of astragalus polysaccharide for treating diabetes and its action mechanism.

Shiyu Liu, Luyao Wang, Zehua Zhang, YuLin Leng, Yan Yang, Xiaoxu Fu, Hongyan Xie, Hong Gao, Chunguang Xie

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 1 pooled it
10.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Research Progress on Chemical Components ofMolecules (Basel, Switzerland) · 2025
    Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Shiyu LiuHospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
Luyao WangHospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
Zehua ZhangHospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
YuLin LengHospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
Yan YangHospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
Xiaoxu FuHospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
Hongyan XieHospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
Hong GaoHospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
Chunguang XieHospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Type 2 diabetes presents a significant global health burden and is frequently linked to serious clinical complications, including diabetic cardiomyopathy, nephropathy, and retinopathy. Astragalus polysaccharide (APS), extracted from

Indexed as

astragalus polysaccharidediabetes complicationsdiabetes mellitusimmunomodulationinsulin resistance

Identifiers

PMID38659573
PMCPMC11039829
OpenAlexW4394687822

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.